Achaogen Company Profile (NASDAQ:AKAO)

Achaogen trades on the NASDAQ under the ticker symbol "AKAO."

Achaogen, Inc. (NASDAQ:AKAO) announced its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.60) by $0.18. The firm had revenue of $1.30 million for the quarter, compared to the consensus estimate of $2.69 million. Achaogen had a negative net margin of 281.88% and a negative return on equity of 86.24%. Achaogen's revenue for the quarter was down 85.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.87) earnings per share. View Achaogen's Earnings History.

10 brokers have issued 12 month price targets for Achaogen's stock. Their forecasts range from $10.00 to $30.00. On average, they anticipate Achaogen's share price to reach $26.00 in the next year. View Analyst Ratings for Achaogen.

Here are some recent quotes from research analysts about Achaogen stock:

• 1. According to Zacks Investment Research, "Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California. " (7/17/2017)
• 2. Cowen and Company analysts commented, "We are assuming coverage of AKAO with an Outperform." (5/5/2017)
• 3. Needham & Company LLC analysts commented, "Achaogen mgmt provided a 4Q16 corporate update yesterday. Company remains on track for plazomicin NDA submission 2H17. Details around manufacturing/ CMC were provided, including role for Pfizer McPherson facility in fill/ finish. An FDA Warning Letter was issued to Pfizer last month for matters unrelated to plazomicin at facility. We assume resolution is likely before PDUFA date in 2018. We await additional information on new oral beta-lactam/ BLI cUTI program (C-Scape), but believe commercial opportunity for oral drug in this indication is one of most attractive areas in antibiotic space." (3/15/2017)
• 4. Aegis analysts commented, "Yesterday after market close, Achaogen announced fourth quarter results, reporting revenue of $10.7 mil vs. street consensus estimates of $12.4 mil and GAAP-EPS of $(1.04) vs. consensus of $(0.49). The EPS miss comes primarily from a $16.9 mil expense recorded in the fourth quarter related to changes in warrants and derivative liabilities that was associated with the capital raise completed in June, 2016. Achaogen is a clinical stage development company, as such we believe the financials are less important, milestones and catalysts tend to drive valuation for these types of companies." (3/15/2017)

Some companies that are related to Achaogen include Lexicon Pharmaceuticals (LXRX), Clinigen Group PLC (CLIN), Sangamo Therapeutics (SGMO), Dynavax Technologies Corporation (DVAX), Acorda Therapeutics (ACOR), Dermira (DERM), Xencor (XNCR), NeuroDerm (NDRM), Epizyme (EPZM), Five Prime Therapeutics (FPRX), Athenex (ATNX), Omeros Corporation (OMER), Amarin Corporation PLC (AMRN), Retrophin (RTRX), REGENXBIO (RGNX), ZIOPHARM Oncology (ZIOP), Intra-Cellular Therapies (ITCI) and Vanda Pharmaceuticals (VNDA).

Achaogen's management team includes the folowing people:

• Bryan E. Roberts Ph.D., Chairman of the Board
• Kenneth J. Hillan, President, Chief Executive Officer, Director
• Blake Wise, President, Chief Operating Officer
• Tobin Schilke, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
• Lee Swem, Senior Vice President, Chief Scientific Officer
• Zeryn Sarpangal, Senior Vice President - Corporate and People Strategy
• Janet Dorling, Chief Commercial Officer
• John C. Doyle, Director
• Halley E. Gilbert Esq., Director
• Kent E. Lieginger, Director

Achaogen's stock is owned by a number of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (14.55%), FMR LLC (12.64%), State Street Corp (3.97%), Vanguard Group Inc. (3.93%), Versant Venture Management LLC (3.57%) and TimesSquare Capital Management LLC (3.04%). Company insiders that own Achaogen stock include Blake Wise, Equity Opportunities Iv Growth, Gary Loeb, Ian Friedland, Kenneth J Hillan, Tobin Schilke and Zeryn Sarpangal. View Institutional Ownership Trends for Achaogen.

Achaogen's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, EAM Investors LLC, Sphera Funds Management LTD., Goldman Sachs Group Inc., Nicholas Investment Partners LP, AXA, Fiera Capital Corp and Ameriprise Financial Inc.. Company insiders that have sold Achaogen stock in the last year include Blake Wise, Gary Loeb, Ian Friedland, Kenneth J Hillan, Tobin Schilke and Zeryn Sarpangal. View Insider Buying and Selling for Achaogen.

Achaogen's stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, TimesSquare Capital Management LLC, Franklin Resources Inc., Vanguard Group Inc., Northern Trust Corp, Lord Abbett & CO. LLC, Artal Group S.A. and Farallon Capital Management LLC. View Insider Buying and Selling for Achaogen.

Shares of Achaogen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Achaogen stock can currently be purchased for approximately $15.84.